M&A Deal Summary

Sentynl Therapeutics Acquires Zokinvy

On May 3, 2024, Sentynl Therapeutics acquired life science company Zokinvy from Eiger BioPharmaceuticals

Acquisition Highlights
  • This is Sentynl Therapeutics’ 1st transaction in the Life Science sector.
  • This is Sentynl Therapeutics’ 1st transaction in the United States.
  • This is Sentynl Therapeutics’ 1st transaction in California.

M&A Deal Summary
Date 2024-05-03
Target Zokinvy
Sector Life Science
Buyer(s) Sentynl Therapeutics
Sellers(s) Eiger BioPharmaceuticals
Deal Type Divestiture

Target

Zokinvy

Palo Alto, California, United States
Zokinvy is a disease-modifying agent that blocks the accumulation of defective progerin and progerin-like proteins which leads to cellular instability and premature aging in children and young adults with progeria. Zokinvy is based in Palo Alto, California.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Sentynl Therapeutics

Solana Beach, California, United States
Category Company
Founded 2011
Sector Life Science
DESCRIPTION

Sentynl Therapeutics, Inc. is a commercial-stage specialty pharma company which specializes in launching unique products and revitalizing marketed brands. Sentynl Therapeutics, Inc. was founded in 2011 and is based in Solana Beach, California.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2024) 1 of 1

Seller(S) 1

SELLER

Eiger BioPharmaceuticals

Palo Alto, California, United States
Category Company
Founded 2008
Sector Life Science
Employees54
Revenue 12M USD (2021)
DESCRIPTION

Eiger BioPharmaceuticals is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of Hepatitis. Our pipeline includes preclinical NCEs from discovery as well as repurposed clinical agents to treat Hepatitis C and Hepatitis D. Eiger BioPharmaceuticals was incorporated in 2008 and is based in Palo Alto, California.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Divestiture) 1 of 2
State (California) 1 of 2
Country (United States) 1 of 2
Year (2024) 1 of 2
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-07-10 Avexitide

Palo Alto, California, United States

Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five Phase 2 clinical studies for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), with U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for both indications and FDA Rare Pediatric Disease Designation in congenital HI. Avexitide is based in Palo Alto, California.

Sell -
Mergr

Product

Company

Legal